Previous Article | Next Article 
Journal of Virology, November 2001, p. 10334-10347, Vol. 75, No. 21
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.21.10334-10347.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Acidic and Aromatic Residues in the
Zta Activation Domain Essential for Epstein-Barr Virus
Reactivation
Zhong
Deng,1
Chi-Ju
Chen,1
Dennis
Zerby,1
Henri-Jacques
Delecluse,2 and
Paul M.
Lieberman1,*
The Wistar Institute, Philadelphia,
Pennsylvania 19104,1 and University
of Birmingham, Birmingham, United Kingdom2
Received 16 April 2001/Accepted 17 July 2001
 |
ABSTRACT |
Epstein-Barr virus (EBV) lytic cycle transcription and
DNA replication require the transcriptional activation function of the
viral immediate-early protein Zta. We describe a series of alanine
substitution mutations in the Zta activation domain that reveal two
functional motifs based on amino acid composition. Alanine
substitution of single or paired hydrophobic aromatic amino acid
residues resulted in modest transcription activation defects,
while combining four substitutions of aromatic residues (F22/F26/W74/F75) led to more severe transcription defects.
Substitution of acidic amino acid residue E27, D35, or E54 caused
severe transcription defects on most viral promoters.
Promoter- and cell-specific defects were observed for some substitution
mutants. Aromatic residues were required for Zta interaction with
TFIIA-TFIID and the CREB-binding protein (CBP) and for stimulation of
CBP histone acetyltransferase activity in vitro. In contrast, acidic
amino acid substitution mutants interacted with TFIIA-TFIID and CBP
indistinguishably from the wild type. The nuclear domain 10 (ND10)
protein SP100 was dispersed by most Zta mutants, but acidic residue
mutations led to reduced, while aromatic substitution mutants led to
increased SP100 nuclear staining. Acidic residue substitution
mutants had more pronounced defects in transcription activation of
endogenous viral genes in latently infected cells and for viral
replication, as measured by the production of infectious virus. One
mutant, K12/F13, was incapable of stimulating EBV lytic replication but had only modest transcription defects. These results indicate that Zta
stimulates viral reactivation through two nonredundant structural
motifs, one of which interacts with general transcription factors and
coactivators, and the other has an essential but as yet not
understood function in lytic transcription.
 |
INTRODUCTION |
Epstein-Barr virus (EBV) is a
human herpesvirus that replicates in the oropharynx and establishes a
latent infection in memory B lymphocytes (reviewed in references
3, 26, and 43). Latent EBV infection is associated with
several human malignancies, including endemic Burkitt's lymphoma,
nasopharyngeal carcinoma,
50% of Hodgkin's disease cases,
and lymphoproliferative disorders in the immunosuppressed. Lytic
replication can be detected in rare opportunistic infections like oral
hairy leukoplakia, but is largely restricted in immunologically healthy
individuals (20). Infectious virus can be detected in most
EBV-positive adults, and it is thought that lytic replication is
required for the lifelong persistence of EBV (23).
Additionally, high antibody titers to lytic antigens correlate with
increase risk of nasopharyngeal carcinoma, suggesting that lytic
replication may increase the probability of an EBV-associated malignancy (13).
Lytic replication requires the coordinated expression of two
viral immediate-early proteins, Zta (also called BZLF1,
ZEBRA, and EB1) and Rta (BRLF1) (16). Zta is a
member of the basic leucine zipper (b-zip) family of DNA-binding
proteins that stimulates transcription of numerous viral genes
essential for lytic replication, as well as several cellular genes of
unknown function (9, 12, 15, 33). Zta binds directly to
the viral origin of lytic replication and recruits the virally encoded
DNA primase and polymerase processivity factors that are essential for
DNA replication (18, 33, 44, 45). Virus lacking Zta is
incapable of lytic cycle gene expression or DNA replication, indicating
that Zta is essential for virus viability (16).
The Zta transcriptional activation domain has been mapped to the
amino-terminal 100 amino acids (11, 17, 30). Replication function is also dependent on the transcription activation domain, and
the two activities are thought to be tightly integrated
(44). In addition to transcription and replication, Zta
can arrest cell cycle progression by a mechanism dependent on the
b-zip domain (6, 7). During lytic
reactivation, Zta localizes and disrupts PML-associated nuclear
domains (ND10/PODs) which are thought to function in viral DNA
replication (2, 5). Zta is subject to several
posttranslational modifications that regulate its function, including
tetradecanoyl phorbol acetate (TPA)-inducible phosphorylation at serine
186, oxidation of cysteine 189, and SUMO-1 modifcation of lysine 12 (2, 4, 27).
The mechanisms of transcription activation by Zta have been
examined in some detail. The amino-terminal transcription activation domain of Zta consists of three functionally redundant modules, but the
specific function of each module has not been fully elucidated (11). Zta can stimulate the formation of the TFIIA and
TFIID complex on naked DNA templates in vitro, and this activity
correlates with transcription activation of a subset of viral promoters
(10, 31). Zta binds to general transcription factors
TFIIA, TBP, and at least one high-molecular-weight component of the
TFIID complex (29, 32). Transcription activation is also
stimulated by cotransfection of the CREB-binding protein (CBP) and
p300, which function as coactivators for numerous promoter-specific transcription factors (1, 51: reviewed in19).
Zta binds strongly to the cysteine-histidine (C/H)-rich regions 1 and 3 of CBP (51). Both the activation domain and the
DNA-binding domain of Zta have been implicated in the binding to CBP
(1, 51). The interaction between Zta and CBP can potently
stimulate CBP nucleosome-specific histone acetyltransferase (HAT)
activity (8). This activity was dependent on the Zta
activation and DNA-binding domains and correlated with the ability of
Zta to bind small oligonucleosomes (8). In addition to CBP
binding, Zta alters the activity of several cellular transcription
factors, including p53, NF-
B, and c-Myb (22, 25, 52).
Transcriptional activation domains have been studied in some detail for
several activators (40). Early studies identified amino
acid compositions that correlated with transcription activities, including acidic stretches, hydrophobic clusters, glutamine- and proline-rich regions, and leucine motifs involved in coactivator binding (41). However, only a few of these activation
regions have been characterized with biophysical techniques, and in
these instances the domains were found to lack structure in the absence of a binding partner (28, 50). These results suggest that activation domains are flexible regions that can adapt a structure to
accommodate multiple interactions with distinct targets.
To better understand the amino acid motifs and potential
structure-function relationship in the Zta activation domain, we have
generated a series of alanine substitution mutations throughout the
first 90 amino acid residues in Zta. The activation domain of Zta
consists of several hydrophobic aromatic amino acid clusters, interspersed with several acidic residues adjacent to glutamine or
proline residues. These two classes of amino acid residues were
targeted by site-directed mutagenesis and then assayed for transcription functions and biochemical activities that have been established previously for Zta. We found that the Zta activation domain
consists of two functionally distinct amino acid compositions that
target different cellular factors to regulate transcription in a
promoter- and cell type-dependent manner.
 |
MATERIALS AND METHODS |
Cells.
HeLa, 293, and D98/HR1 cells were maintained in
Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum (Gibco-BRL), glutamine, and penicillin-streptomycin in a
5% CO2 incubator at 37°C. DG75 and RAJI
lymphoblastoid cells were maintained in RPMI medium supplemented with
10% fetal bovine serum, glutamine, and antibiotics in a 5%
CO2 incubator at 37°C. The 293 EBV-positive BZLF1-knockout cells (ZKO) were maintained in RPMI medium supplemented with 10% fetal bovine serum, 100 µg hygromycin per ml, glutamine, and antibiotics in a 5% CO2 incubator at 37°C.
ZKO cells carry the gene for green fluorescent protein (GFP) under
control of the human cytomegalovirus immediate-early promoter-enhancer
(16).
Plasmid and recombinant proteins.
The EBV Zta protein was
expressed in transient-transfection assays from either ZtaSR
, a
simian virus 40-based enhancer system (48), or Zta-pcDNA3,
a cytomegalovirus-based promoter system (Invitrogen). The BZLF1
promoter-luciferase construct (ZpLuc) was generated by amplification of
BZLF1
220 to +12 as an NheI-HindIII fragment in pGL3BASIC (Promega). The BRLF1 promoter-luciferase construct (RpLuc) was generated by amplification of BRLF1
178 to +28
as an NheI-HindIII fragment in pGL3BASIC
(Promega). The Mp promoter-luciferase construct (MpLuc) was generated
by amplification of BMRF1
300 to +1 as an
NheI-HindIII fragment in pGL3BASIC. Z7E4TCAT (gift of M. Carey) and BHLF1 CAT have
been described previously (34). Zta deletion mutants were
generated by PCR mutagenesis and cloned as
EcoRI-BamHI fragments in pBKSII (Stratagene) for
in vitro translation with T3 RNA polymerase. Zta alanine substitution mutants were generated by overlap PCR mutagenesis and cloned in the
pSR
296 vector for mammalian cell expression (48).
Glutathione S-transferase (GST)-CBP C/H1 and C/H3 have been
described previously (51).
Transfections and reporter assays.
HeLa, DG75, D98/HR1, and
293 ZKO cells were transfected using Lipofectamine 2000 (LF2000)
reagent (Gibco-BRL) according to the manufacturer's protocol. Briefly,
6 × 105 adherent cells (HeLa, D98/HR1, and
293 ZKO) were seeded in six-well plates 12 to 16 h prior to
transfection. For suspension cells (DG75), 8 × 105 cells were passaged into 24-well plates
immediately before transfection. Plasmid effector DNA was added at 0.5 to 1 µg, depending on the experiment, and the BZLF1-Luc, BRLF1-Luc,
and BMRF1-Luc reporter plasmids were added to 0.5 µg. For each well
of cells to be transfected, the DNA was diluted into 250 µl of
Opti-Mem I reduced serum medium (Gibco-BRL), and 2 µl of LF2000
reagent was diluted into 250 µl of Opti-Mem I medium separately. The
diluted DNA was combined with the diluted LF2000 reagent. After
incubation at room temperature for 20 min, the DNA-LF2000 reagent
complexes were added to each well. Transfected cells were harvested at
48 h posttransfection. Luciferase assays were performed by using
the luciferase assay system (Promega). The results of luciferase assays
were based on experiments performed at least in triplicate on multiple
independent transfections. The error bars show the standard error of
the mean for three to nine separate determinations. Expression levels
of all activator proteins were monitored by Western blot analysis.
EMSAs.
The magnesium-agarose electrophoretic mobility shift
assay (EMSA) was described previously (31). Approximately
50 to 150 ng of Zta derivative was incubated with
32P-labeled Z5E4T promoter
(100 fmol) with 100 ng of GST-CBP(C/H1) or GST-CBP(C/H3) protein.
Recombinant TFIIA and affinity-purified HeLa-derived TFIID were
generated as previously described (39).
GST interaction assays.
GST fusion proteins were purified by
glutathione-Sepharose chromatography and dialyzed to remove free
glutathione. Purified GST proteins were incubated with
35S-labeled in vitro-translated Zta proteins and
then precipitated with glutathione-Sepharose, washed four times, and
eluted with sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) loading buffer, essentially as described (38).
Zta mutants were assayed for interaction with GST-C/H1 and -C/H3 by the
Mg-EMSA as described previously (8).
HAT assay.
Zta mutants (300 ng) were expressed and purified
as hexahistidine amino-terminal fusion proteins from pQE8 as described
previously (31). Purified Zta proteins were incubated with
His-tagged full-length baculovirus CBP (gift of D. Thanos) and 200 ng
of small oligonucleosomes with 0.25 µCi of
[3H]acetyl coenzyme A (Amersham) in a 30-µl
reaction containing HAT buffer (50 mM Tris [pH 8.0], 5% glycerol,
0.1 mM EDTA, 50 mM KCl, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, and 10 mM sodium butyrate) at 30°C for 1 h. The
reactions were resolved by SDS-15% PAGE. The gel was enhanced using
Entensify (NEN) and analyzed by autoradiography.
Western blotting.
Cells were harvested, washed once with
phosphate-buffered saline (PBS), and lysed in SDS-PAGE loading buffer
by boiling for 10 min. Equal amounts of protein in sample buffer were
loaded on SDS-8% PAGE gel and separated by gel electrophoresis. The
gels were transferred by electroblotting to a nitrocellulose membrane. The primary antibodies used include EBV p52/50 anti-EA-D monoclonal antibody (Advanced Biotechnologies), EBV anti-Rta (Argene), anti-HA (Boehringer), and a rabbit polyclonal antibody raised against Zta.
Signals were visualized by enhanced chemiluminescence (Amersham).
Indirect immunofluorescence.
D98/HR1 cells were transfected
with Zta mutants using LF2000 on coverslips in 12-well plates and fixed
in 1% paraformaldehyde at 48 h posttransfection. The fixed cells
were permeabilized by incubation in 0.2% Triton (20 min on ice) and
incubated with primary antibodies to Zta (rabbit polyclonal 1:1,000
dilution) or monoclonal antibody 1150 specific for the ND10 SP100
protein (1:100 dilution). Mouse antibody was visualized with
fluorescein isothiocyanate, and rabbit antibody was visualized with
Texas Red, essentially as described previously (5). Cells
were then stained for DNA with Hoechst 33258 and mounted with
Fluoromount G (Fisher Scientific). Cells were analyzed with a Leitz
Fluovert inverted microscope equipped with a digital camera.
Images were obtained using software from QED Imaging (Pittsburgh, Pa.).
Infection studies and FACS.
Virus production was induced by
transfecting 1 µg of various Zta expression plasmids, including
the vector pcDLSR
296, into 293 ZKO cells. Supernatants were
harvested from these cells 48 h posttransfection and passed into
six-well plates through 0.8-µm filter pores (16). About
2 × 105 Raji cells in 200 µl of complete
RPMI medium were added to each well containing the supernatants from
different transfections. Approximately 100 ng/ml TPA was also added to
each well to help to identify the GFP. The virus titers were determined
by analyzing the percentage of green Raji cells by
fluorescence-activated cell sorter (FACS) analysis 4 days after
infection. Briefly, cells were collected by centrifugation for 5 min at
2,000 rpm and washed once with cold 1× PBS. About 5 × 105 cells were then resuspended in 0.5 ml of PBS
for FACS analysis using an EPICS XL flow cytometer (Coulter
Corporation, Hialeah, Fla.).
 |
RESULTS |
Promoter-specific defects of Zta alanine substitution mutants.
A series of alanine substitution mutations in the Zta amino-terminal
activation domain (amino acids 1 to 90) were generated by site-directed
mutagenesis and assayed for transcription activation function on a
series of Zta-responsive reporter genes by transient-transfection assay
in HeLa cells. A highly sensitive synthetic reporter construct containing seven Zta binding sites upstream of the adenovirus E4 TATA
box region (Z7E4TCAT) was assayed. Alanine
substitutions at amino acids D27/Q28, Q34/D35, and P53/E54 caused the
most pronounced transcription defects (Fig.
1A). These amino acids are notable for
containing a single acidic residue in a hydrophobic patch. Alanine
substitution of Y33/Q34 had no effect on transcription, indicating that
the glutamine at position 34 was not as important as the aspartic acid
at position 35.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
Zta activation domain mutants have promoter-specific
defects. Alanine substitution mutations in the Zta activation domain
were assayed for transcription activation of Z7E4TCAT (A)
or BHLF1 CAT (B) in transient-transfection assays in HeLa cells. (C)
Zta mutants were analyzed by Western blot of transfected cell extracts
with polyclonal rabbit antisera directed against Zta. (D) Amino acid
sequence of Zta activation domain. Amino acid substitutions causing
defects in Z7E4TCAT are noted in bold, and those defective
in BHLF1 CAT are underlined.
|
|
The same set of alanine substitution mutations were assayed for
transcription activation of the EBV BHLF1 promoter. The Zta binding
sites in the BHLF1 promoter are an essential component of OriLyt and
direct transcription of a repetitive transcript that encodes a protein
of unknown function. Alanine substitution mutations at K12/F13,
F22/F26, L48/W49, and W74/F75 caused defects most notably in activation
of BHLF1-CAT (Fig. 1B). Single amino acid substitutions at
positions W74 and F26 had less dramatic effects on transcription,
and the combination F22/F26/W74/F75 caused the most extreme
defect in transcription. These results suggest that hydrophobic
aromatic amino acid residues function cooperatively to stimulate
transcription from BHLF1. Western blotting of Zta protein levels after
a typical transfection indicated that most alanine substitution mutants
were expressed at similar levels (Fig. 1B).
To further explore the observation that the Zta activation domain had
promoter-specific activation functions, we compared several other
EBV-derived promoters for their responsiveness to Zta mutants (Fig.
2). The BZLF1 promoter (Zp), the BMRF1
promoter (Mp), and the BRLF1 promoter (Rp) have been shown previously
to be Zta responsive in the transient-transfection assay. Transcription activation of Zp was most significantly reduced by alanine substitution mutations in L48/W49 and F22/F26/W74/F75 (Fig. 2A). However, mutations in Q34/D35 and P53/E54 reduced transcription to less than 20% of the
wild-type level, indicating that Zp depended on both acidic and
hydrophobic residues in the Zta activation domain. Mp and Rp were
similar to Zp, although they showed a greater dependence on amino acid
residues D27/Q28 and Q34/D35 (Fig. 2B and C). Mp was more sensitive to
mutations in W74/F75 than was Zp or Rp. In general, mutations in both
acidic and aromatic residues resulted in strong transcription defects.
These results suggest that the Zta activation domain consists of two
motifs differentiated by the composition of acidic or hydrophobic
aromatic amino acid residues. These motifs appear to have
promoter-specific activation functions that cooperate for full
activation of complex viral promoters such as Zp, Rp, and Mp.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of Zta activation domain mutants on EBV early
lytic promoters. (A, B, and C) The BZLF1 (Zp-Luc), BMRF1 (Mp-Luc), and
BRLF1 (Rp-Luc) constructs were assayed for Zta transcription activation
in transient-transfection assays in HeLa cells. Zta alanine
substitution mutants are indicated below. (D) Zta mutants were analyzed
for expression levels by Western blotting analysis.
|
|
Zta activation domain properties in various cell types.
Lytic
reactivation by Zta requires transcription stimulation of viral genes
embedded in a chromatin-repressed latent viral genome. Transiently
transfected reporter plasmids may not recapitulate chromatin structure,
and therefore may not reveal all of the transcription properties
required by Zta for reactivation of latent virus. Consequently, we
assayed the ability of Zta to stimulate viral gene expression in
latently infected D98/HR1 cells.
Zta alanine substitution mutants were transfected into D98/HR1 cells
and assayed by Western blotting for the expression of the viral
proteins Rta, EA-D, and Zta, encoded by the viral genes BRLF1, BMRF1,
and BZLF1, respectively (Fig. 3A). We
found that Zta acidic amino acid residue mutants Q34/D35 and P53/E54
were significantly reduced for activation of Rta and EA-D. In contrast, the aromatic residue substitution mutants L48/W49 and F22/F26/W74/F75 were not significantly reduced for Rta and EA-D activation. The acidic residue substitution mutants were expressed at lower
levels in D98/HR1 cells, while the aromatic residue substitution
mutants were expressed at higher levels, suggesting that
these residues may contribute to the stability of Zta in these cell
types (Fig. 3A, lower panel).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 3.
Cell-specific defects of Zta activation domain mutants.
(A) Zta alanine substitution mutants were transfected into D98/HR1
cells and assayed 72 h posttransfection by Western blot for
expression of Rta (upper panel), EA-D (middle panel), and Zta (lower
panel). (B) Zta mutants were assayed for transcription activation of
the Mp-Luc reporter plasmid in DG75 lymphoblastoid cells.
|
|
EBV latently infects lymphoblastoid cells, and it is possible that Zta
activation functions may differ in the various cell types that it
infects. To determine whether Zta activation domain function was
different in B lymphocytes, we assayed Zta substitution mutant
transcription activation properties in the EBV-negative lymphoblastoid
cell line DG75 (Fig. 3B). We found that the acidic amino acid
substitution mutants D27/Q28, Q34/D35, and P53/E54 were significantly
reduced for activation of Mp-Luc, similar to what was observed in HeLa
cells. We also found that aromatic residue substitution mutants L48/W49
and F22/F26/W74/F75 were also reduced, although not as extensively as
was observed in HeLa cells. W74/F75 was significantly more reduced for
activation in HeLa cells than in DG75 cells (compare Fig. 2 and 3B). As
was found for D98/HR1 cells, acidic residue substitution mutants had
substantially reduced protein expression levels, while the aromatic
substitution mutants had increased Zta expression levels (Fig. 3B,
lower panel). Similar patterns of viral gene activation and Zta mutant
stability were observed in EBV-positive Burkitt's lymphoma cell lines
Raji and Akata, as well as in EBV-negative Akata cells (data not
shown). The decreased stability of acidic residue substitution mutants Q34/D35 and P53/E54 is unlikely to account fully for the reduced transcription activation of these mutants, since similar low expression of wild-type Zta did not correlate with target gene activation levels
(Fig. 3B lower panel, and data not shown). These findings suggest that
the Zta activation domain may interact with cell-specific factors that
regulate Zta transcription activation and Zta protein stability.
Zta aromatic amino acid residues confer CBP binding.
We and
others have shown that Zta binds the C/H1 and C/H3 domains of CBP
(1, 51). To determine what amino acid residues in the Zta
activation domain confer this binding, we assayed in vitro-translated
Zta proteins for their ability to bind purified GST-C/H1 or GST-C/H3 in
vitro (Fig. 4). Full-length Zta bound efficiently to GST-C/H1 and GST-C/H3, but did not bind significantly to
GST alone (Fig. 4A). Deletion of the amino-terminal activation domain
(
2-141) completely eliminated CBP binding. Deletion of the
amino-terminal half (
3-68) or the carboxy-terminal half of the
activation domain (
66-141) eliminated CBP binding. Deletion of amino
acids 94 to 140 (
94-140) had no significant effect on Zta-CBP
binding. Similarly, deletion of the extreme C-terminal domain of Zta
(
198-245) had little effect on CBP binding. These results indicate
that Zta amino acid residues 2 to 94 were required for CBP binding in
vitro.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 4.
Zta activation domain mutants disrupt CBP binding in
solution. (A) Zta deletion mutants were 35S labeled by in
vitro translation and assayed for binding to GST-CBP-C/H1 or -C/H3
domain. (B) Zta alanine substitution mutants were assayed for binding
to GST-CBP-C/H1 or -C/H3 proteins. (C) Schematic of Zta functional
domains.
|
|
To further map the interaction of the Zta activation domain with CBP
and to better correlate transcription properties with CBP binding, we
assayed several of the Zta substitution mutants for binding to
GST-CBP-C/H1 and -C/H3 (Fig. 4B). We found that F22A and F26A had
reduced but detectable binding to both domains of CBP, while the
combination F22A/F26A reduced CBP binding to nearly undetectable
levels. Alanine substitution of W74 alone eliminated CBP binding, and
all combinations of mutants containing W74, including W74/F75 and the
quadruple substitution mutant F22/F26/W74/F75, had undetectable binding
to CBP. In contrast, substitution mutations in L48/W49 did not
eliminate CBP binding, nor did substitution of the acidic amino acids
Q34/D35 or P53/E54. These results indicate that combinations of
hydrophobic amino acids contribute to stable interaction with both the
C/H1 and C/H3 domains of CBP.
The interaction of in vitro-translated Zta with CBP domains may not
reflect the more selective binding required for transcription activation in vivo. To better address this concern, we assayed the
ability of GST-C/H1 and GST-C/H3 to interact with Zta bound to the
Z7E4T promoter using EMSA (Fig
5A). The panel of Zta alanine substitution mutations assayed in Fig. 1 and 2 were compared for their
ability to form stable EMSA-resolvable complexes with GST-C/H1 (top
panel) and GST-C/H3 (middle panel). Zta binding with GST alone is shown
in the lower panel. Quantitation of the binding reactions indicated
that multiple aromatic amino acid residues were essential for CBP
complex formation (Fig. 5D). In particular, we found that K12/F13,
F22/F26, L48/W49, and W74/F75 were significantly reduced for CBP
binding. The quadruple mutant F22/F26/W74/F75 showed completely
disrupted interaction with CBP in this assay, again suggesting that the
combinations of aromatic amino acids cooperate for stable binding to
CBP. The binding to CBP correlated well with the transcriptional
activation of the BHLF1 promoter (compare Fig. 1B and 5D).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 5.
Aromatic residue substitutions disrupt CBP-promoter
recruitment and stimulation of HAT activity. (A) Zta alanine
substitution mutants were assayed by Mg-agarose EMSA for binding
to GST-CBP-C/H1 (top panel), GST-CBP-C/H3 (middle panel), or GST
alone (lower panel) in a complex with the
Z7E4T promoter probe. (B) Zta substitution mutants were
assayed for the ability to stimulate CBP nucleosome-directed HAT
activity in vitro. Acetylated nucleosomes were visualized by
fluorography of SDS-PAGE gels. (C) Coomassie brilliant blue staining of
recombinant Zta substitution mutants used in panels A and B. (D)
Quantitation of CBP EMSA (black bars) and HAT activity (grey bars)
shown in A and B above.
|
|
Amino acid residues required for stimulation of CBP HAT
activity.
We have found previously that Zta stimulates the HAT
activity of CBP directed towards small oligonucleosomes
(8). This assay requires full-length CBP and may better
reflect the in vivo transcription activation functions of Zta than the
binding assays with CBP fragments. The panel of Zta alanine
substitution mutants were assayed for their ability to stimulate HAT
activity of affinity-purified full-length CBP (Fig. 5B). Quantitation
of histone acetylation (Fig. 5D) indicated that the same aromatic
residues required for EMSA binding were important for HAT stimulation.
Specifically, K12/F13, F22/F26, L48/W49, W74/F75, and F22/F26/W74/F75
were most significantly reduced for stimulation of HAT activity.
Recombinant Zta protein abundance was similar in all cases (Fig. 5C).
These results indicate that hydrophobic aromatic residues are essential for stimulation of CBP HAT activity. This experiment also demonstrates that acidic residues Q34/D35 and P53/E54 stimulate HAT activity like
wild-type Zta despite their transcription defect on several reporter plasmids.
Amino acid residues required for TFIIA-TFIID promoter complex
formation.
Zta can also stimulate the formation of a stable
interaction between core promoter sequences and the TFIIA-TFIID general
transcription factor complex. The panel of Zta mutants were assayed by
EMSA for their ability to stimulate the Z-D-A complex with the
Z7E4T promoter (Fig.
6). A representational EMSA for each
mutant is shown (Fig. 6A). The average of at least three independent
EMSA experiments was quantitated and represented graphically (Fig. 6B).
Z-D-A complex formation was dependent on aromatic amino acid residues
K12/F13, F22/F26, L48/W49, Y64/H65, W74/F75, and F22/F26/W74/F75. The
substitution mutations that disrupted Z-D-A complex formation were
similar to those that disrupted CBP binding and BHLF1 transcription activation (compare Fig. 6B, 5D, and 1B).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 6.
Formation of the Zta-TFIID-TFIIA-promoter complex with
Zta activation domain mutants. (A) Mg-agarose EMSA was used to analyze
Zta stimulation of TFIIA-TFIID complex formation on the
Z7E4T promoter DNA probe. Complexes were formed in the
absence ( ) or presence (+) of Zta mutants as indicated above each
lane. (B) The average values for at least three independent Z-D-A
complex assays were quantitated for each Zta substitution mutant.
|
|
Zta activation domain function in ND10 dispersion.
EBV
reactivation induced by Zta transfection correlates with the dispersion
of ND10-associated proteins from the characteristic patterns of
punctate nuclear bodies (2, 5). Zta activation domain
mutants were assayed for their ability to disrupt ND10 bodies using the
SP100 protein as a marker for ND10 integrity. We focused on a subset of
Zta mutants that were found to have biochemical and functional defects
in the previous set of experiments. D98/HR1 cells transfected with
control vector pcDNA3 had
10 to 20 SP100-positive nuclear domains
characteristic of ND10 (Fig. 7, top
panel). Cell transfected with wild-type Zta resulted in a diffusion of
ND10 and enhanced staining of SP100. Substitution K12/F13 resulted in
weak dispersion of ND10 and no enhanced staining of SP100. F22/F26 had
a staining pattern similar to the wild type. Acidic residue mutations
Q34/D35 and P53/E54 caused SP100 dispersion but did not enhance SP100
expression levels. In contrast, aromatic residue mutations L48/W49 and
F22/F26/W74/F75, which were defective for binding to CBP and
TFIIA-TFIID and for BHLF1 transcription activation, caused a massive
increase in SP100 staining and no discernible ND10 structure (Fig. 7).
These results suggest that Zta activation domain
functions contribute to the dispersion of ND10 and the
accumulation of nuclear SP100 protein.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 7.
Dispersion of ND10 protein SP100 by Zta activation
domain mutants. (A) A subset of Zta alanine substitution mutants
(indicated to the left of each panel) were transfected into D98/HR1
cells and assayed 48 h posttransfection by indirect
immunofluorescence. Antibodies specific for Zta (left panel) were
detected with Texas Red, and antibodies specific for SP100 (middle
panel) were detected in green with fluorescamine. The merge of the two
images is shown in yellow (right panel).
|
|
Transcription activation and DNA replication of BZLF1-null
EBV.
The Zta alanine substitution mutants were next assayed for
their ability to stimulate lytic gene expression and viral DNA replication in the absence of potential interfering effects of virally
encoded Zta. 293 cells harboring a recombinant viral genome lacking Zta
coding sequences (ZKO) were used for transcription reactivation and
replication studies (16). Transfection of wild-type Zta
into ZKO cells resulted in strong stimulation of EA-D and Rta gene
expression, as assayed by Western blotting (Fig.
8A). Alanine substitution at acidic
amino acid residues D27/Q28, Q34/D35, and P53/E54 gave the most
dramatical reductions in activation of EA-D and Rta. We also observed
that aromatic amino acid substitution L48/W49 and the quadruple
substitution F22/F26/W74/F75 were diminished relative to wild-type Zta
activation levels. In contrast to our studies with D98/HR1 and DG75
cells (Fig. 3), most Zta mutants were expressed to similar levels (Fig.
8A, top panel). These results indicate that in the context of a latent
virus lacking endogenous wild-type Zta, transcription
activation requires both the acidic and hydrophobic activation surfaces
of Zta.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 8.
Reactivation of BZLF1-knockout EBV. (A) Zta substitution
mutants were transfected into 293 ZKO cells and assayed by Western
blotting for expression of Zta, EA-D, and Rta, as indicated. (B)
Supernatants from transfected 293 ZKO cells were measured for
infectious virus production by superinfection of Raji cells. Raji cell
superinfection was quantitated by FACS analysis of GFP-positive
cells.
|
|
The ability of Zta substitution mutants to stimulate viral replication
and infectious virus production was assayed by the GFP-positive
conversion of Raji cells. Recombinant EBV genomes have an integrated
GFP gene that can be used to assay infected cell number
(16). Filtered supernatants from transfected ZKO cells
were used to superinfect Raji cells, which were quantitated by FACS
analysis. As expected, acidic residue substitutions that abrogated transcription activation caused defects in progeny
virus production (Fig. 8B). Similarly, the quadruple aromatic
substitution F22/F26/W74/F75 was significantly reduced for progeny
virus production relative to wild-type Zta. However, L48/W49 did not
show significant defects in progeny virus production, although its
transcription was reduced to less than 30% of wild-type activity.
These results indicate that the transcription activation function of
the acidic amino acid residues (D27, D35, and E54) are most critical
for viral replication in 293 cells. Interestingly, K12/F13, which did
not show significant defects in transcription activation of EA-D and
Rta (Fig. 8A), was reduced to less than 10% of wild-type Zta for
production of progeny virus. This is consistent with a DNA
replication-specific function for Zta through amino acids K12 and F13
(44).
 |
DISCUSSION |
Zta is a multifunctional protein essential for EBV lytic cycle
gene expression and viral DNA replication (36, 47). Lytic cycle gene expression requires Zta transcription activation of numerous
and diverse gene promoters, in various cell types and conditions. These
requirements have resulted in a complex and multifaceted transcription
activation domain. Previous truncation mutagenesis revealed that the
Zta activation domain consists of three functionally redundant modules
that reside within the first 90 amino acid residue of Zta
(11). Mutagenesis studies of other transcription
activators, including herpes simplex virus VP16 and Saccharomyces
cerevisiae GCN4, reveal that both bulky hydrophobic clusters and
acidic amino acid residues are important for activation function
(24, 37, 42). We have observed that the Zta activation domain consists largely of hydrophobic amino acids with a repetitive pattern of aromatic residues and patches of acidic residues adjacent to
glutamine or proline. In this work, we found that alanine substitution of aromatic and acidic residues disrupted Zta transcription activation function in a promoter- and cell type-dependent manner. Specifically, we found that combinations of hydrophobic residues were important for
transcription activation of the BHLF1, BZLF1, BMRF1, and BRLF1 promoters in HeLa and 293 cells. In contrast, acidic residues were
important for activation of the synthetic construct
Z7E4T and the viral BMRF1 and BRLF1 promoters in
most cell types. Acidic residues were most important for transcription
activation and reactivation of latent virus in D98/HR1 (Fig. 3) and 293 ZKO infected cells (Fig. 8). Biochemical analysis of Zta mutants
revealed that combinations of hydrophobic aromatic residues were
important for interactions with CBP and the TFIIA-TFIID core promoter
binding factors (Fig. 2 to 5). No obvious biochemical defect was found for acidic amino acid substitution mutants, suggesting that interaction with factors other than CBP and TFIIA-TFIID was disrupted. Taken together, these results suggest that Zta has two distinct activation interfaces with nonredundant functions essential for lytic
cycle gene expression and replication (Fig.
9).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 9.
Distinct targets of the acidic and aromatic
residues in the Zta activation domain. Aromatic residues were important
for CBP and TFIIA-TFIID interactions, Hp transcription activation, and
Zta protein degradation. Acidic residues were essential for Rp, Mp, and
Zp transcription and viral DNA replication and increase Zta stability.
K12 and F13 were essential for replication and SUMO-1 modification
(2).
|
|
The most notable conclusion from these studies was that acidic amino
acid residues (D27, D35, and E54) were essential for Zta transcription
activation of Rta and EA-D from latently infected cells, but had no
obvious disruption of CBP and TFIIA-TFIID complex formation (Fig. 8).
Acidic amino acid residue substitutions were similarly reduced in
Burkitt's lymphoma cells (data not shown) and for the
Z7E4T promoter in HeLa cells (Fig. 1). Acidic
amino acid substitutions had no effect on CBP binding (Fig. 4 and 5), stimulation of CBP HAT activity (Fig. 5), or TFIIA-TFIID promoter complex formation (Fig. 6). Thus, it is likely that Zta interacts through these acidic residues with some other component of the transcriptional machinery besides CBP or TFIIA-TFIID. It is possible that these acidic residues promote conformational changes in these target factors that alter their activity in transcription, but have no
detectable effect on their stable association with Zta as measured in
these studies. It seems unlikely that mutations in acidic residues
cause global changes in Zta structure, since these mutations have
nearly wild-type transcription activity on the BHLF1 promoter in HeLa
cells (Fig. 1). The strong dependence on acidic residues in 293 and
Burkitt's lymphoma cells may reflect an inactivation of the CBP
pathway in these cells. 293 cells contain adenovirus E1A, which can
inactivate CBP, potentially rendering the hydrophobic activation module
of Zta ineffective. Thus, in E1A-positive cells such as 293, the
dependence on the acidic module may be more pronounced. A similar
inactivation of CBP may occur in Burkitt's lymphoma cells, but this
has not been established.
The hydrophobic residues in the Zta activation domain affected
transcription when mutated in combination, but not when mutated individually. A similar cumulative effect of hydrophobic amino acid
mutations was observed for the activation domain of yeast GCN4.
Mutation of hydrophobic clusters reduced transcription weakly, while
combination of hydrophobic mutations resulted in more dramatic transcription defects. Combinations of hydrophobic mutations in GCN4
led to the loss of interaction with TFIID, SAGA, and holo-RNA polymerase (14). A very similar observation was made for
Zta; combinations of hydrophobic aromatic residues led to the loss of
interaction with TFIID-TFIIA and coactivator CBP. In both cases, the
same amino acids mediated interactions with distinct transcription factor targets. Precisely how the same activation surface recruits these two biochemically distinct targets remains unclear. One possibility is that the same surface recruits these factors mutually exclusively and sequentially, which has been shown for the estrogen receptor recruitment of the nuclear hormone family of coactivators (46). Alternatively, Zta may recruit both factors
simultaneously through a large activation surface.
The requirements for lytic DNA replication and production of infectious
virus correlated well with transcription activation function,
indicating that transcription of viral genes is a principal function of
Zta (Fig. 8). However, hydrophobic mutation L48/W49 reduced
transcription to less than 30% of wild type, yet produced similar
levels of infectious virus, suggesting that production of virus occurs
efficiently even with reduced levels of some viral transcripts.
Interestingly, substitution mutations at K12 and F13 resulted in a
severe loss of viral replication and infectious virus production but
only minor defects in transcription activation. This substitution
mutant has been shown to be defective for lytic replication in a
reconstituted transfection system, consistent with our results using
recombinant virus lacking Zta (44). K12/F13 was found to
be important for recruitment of virally encoded DNA replication
proteins (18, 44). K12/F13 had minimal transcription defects in transient-transfection assays, but was reduced for CBP-C/H1
binding and TFIIA-TFIID complex formation (Fig. 2, 4, and 6). Thus,
mutation of K12/F13 may have additional effects on the folding of the
Zta activation domain that reduce most biochemical activities. However,
the severe reduction in replication is most consistent with the loss of
recruitment of EBV replication proteins.
Zta amino acid residue K12 has been shown to be the site of
modification by SUMO-1, a ubiquitin-like protein that can be conjugated to lysine residues on proteins associated with ND10 formation and viral
replication domains (2, 35). We analyzed several Zta
proteins for their effect on ND10 structure by assaying the ND10-associated protein SP100 after transient transfection in D98/HR1
cells (Fig. 7). The K12/F13 mutant was attenuated for SP100 dispersion,
suggesting a correlation between Zta SUMO-1 modification of Zta, ND10
dispersion, and EBV lytic replication. However, acidic substitution
mutants Q34/D35 and P53/E54, which failed to stimulate transcription in
D98/HR1 cells and were replication defective in ZKO cells, dispersed
SP100 structures. This indicates that dispersion of SP100 is not
sufficient for viral reactivation and replication. Interestingly, the
aromatic substitution mutations L48/W49 and F22/F26/W74/F75 led to an
increase SP100 levels in Zta-positive cells, suggesting that Zta also
regulates SP100 accumulation. Additional studies will be required to
determine if Zta alters the stability of SP100 and whether Zta has a
similar effect on other ND10-associated proteins, like PML.
SUMO-1 modification has been proposed to compete with ubiquitin
modification to regulate the stability of target proteins. Interestingly, we found that several Zta activation domain mutants had
substantially different stability in some cell types. Specifically, the
acidic residue substitution mutants had reduced stability while the
aromatic substitutions had increased stability in D98/HR1 and in
lymphoblastoid cells (Fig. 3). Interactions between activation domains
and basal transcription factors can mark activators for ubiquitin-mediated degradation (49). While we have not
identified a ubiquitination site on Zta, our data are consistent with a
model in which the activation domain contributes to protein stability through amino acid residues involved in transcription activation function. A similar observation has been made for the
ubiquitin-mediated degradation of p53, which is targeted by CBP C/H1
domain binding to the p53 activation domain (21).
Mutations in Zta aromatic residues L48/W49 and F22/F26/W74/F75 that
abrogate binding to CBP led to a large increase in Zta stability in
D98/HR1 and lymphoblastoid cells (Fig. 3), suggesting that Zta
association with CBP may similarly regulate Zta stability.
The mutational analysis of the Zta activation domain provides some
insight into the mechanism of Zta-stimulated transcription and DNA
replication. Our data indicate that Zta contains two compositionally and functionally distinct activation motifs (Fig. 9). Hydrophobic aromatic residues were essential for CBP and TFIIA-TFIID complex formation in vitro and had significant effects on Zta stability in
vivo. Although we did not see dramatic effects of aromatic residue
substitutions in the replication and reactivation studies in vivo, this
may be a result of the relatively conservative mutation to alanine.
More radical substitutions of these aromatic residues are more likely
to reveal significant replication and reactivation defects in vivo. The
acidic residues gave clear phenotypes in replication and reactivation
but were not important for interactions with CBP or TFIIA-TFIID. Acidic
residue mutations led to decreased stability of Zta in lymphoblastoid
cells, suggesting that these residues stabilize wild-type Zta. The
cellular targets that mediate the acidic residue activation and
replication function and whether these are distinct from the targets of
the Zta aromatic residues remain important unsolved questions for
future studies.
 |
ACKNOWLEDGMENTS |
The first two authors contributed equally to this work.
We thank J. Sixby, D. Hayward, and S. Speck for supplying cell lines
and Winnie So for excellent technical assistance.
This work was supported by grants from NIH (GM 54687), American Cancer
Society, and the Leukemia & Lymphoma Society (to P.M.L.) and an NCI
Core Grant to the Wistar Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Wistar
Institute, Philadelphia, PA 19104. Phone: (215) 898-9491. Fax:
(215) 898-0663. E-mail: lieberman{at}wistar.upenn.edu.
 |
REFERENCES |
| 1.
|
Adamson, A. L., and S. Kenney.
1999.
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.
J. Virol.
73:6551-6558[Abstract/Free Full Text].
|
| 2.
|
Adamson, A. L., and S. Kenney.
2001.
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
J. Virol.
75:2388-2399[Abstract/Free Full Text].
|
| 3.
|
Babcock, G. J.,
L. L. Decker,
M. Volk, and D. A. Thorley-Lawson.
1998.
EBV persistence in memory B cells in vivo.
Immunity
9:395-404[CrossRef][Medline].
|
| 4.
|
Baumann, M.,
H. Mischak,
S. Dammeier,
W. Kolch,
O. Gires,
D. Pich,
R. Zeidler,
H. J. Delecluse, and W. Hammerschmidt.
1998.
Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation.
J. Virol.
72:8105-8114[Abstract/Free Full Text].
|
| 5.
|
Bell, P.,
P. M. Lieberman, and G. G. Maul.
2000.
Lytic but not latent replication of Epstein-Barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins.
J. Virol.
74:11800-11810[Abstract/Free Full Text].
|
| 6.
|
Cayrol, C., and E. Flemington.
1996.
G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP)domain of the Epstein-Barr virus transactivator Zta.
J. Biol. Chem.
271:31799-31802[Abstract/Free Full Text].
|
| 7.
|
Cayrol, C., and E. K. Flemington.
1996.
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.
EMBO J.
15:2748-2759[Medline].
|
| 8.
|
Chen, C.-J.,
Z. Deng,
A. Y. Kim,
G. A. Blobel, and P. M. Lieberman.
2001.
Stimulation of CREB binding protein nucleosomal histone acetyltransferase activity by a class of transcriptional activators.
Mol. Cell. Biol.
21:476-487[Abstract/Free Full Text].
|
| 9.
|
Chevallier, G. A.,
E. Manet,
P. Chavrier,
C. Mosnier,
J. Daillie, and A. Sergeant.
1986.
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.
EMBO J.
5:3243-3249[Medline].
|
| 10.
|
Chi, T., and M. Carey.
1996.
Assembly of the isomerized TFIIA-TFIID-TATA ternary complex is necessary and sufficient for gene activation.
Genes Dev.
10:2540-2550[Abstract/Free Full Text].
|
| 11.
|
Chi, T., and M. Carey.
1993.
The ZEBRA activation domain: modular organization and mechanism of action.
Mol. Cell. Biol.
13:7045-7055[Abstract/Free Full Text].
|
| 12.
|
Countryman, J. K.,
L. Heston,
L. Gradoville,
H. Himmelfarb,
S. Serdy, and G. Miller.
1994.
Activation of the Epstein-Barr virus BMRF1 and BZLF1 promoters by ZEBRA in Saccharomyces cerevisiae.
J. Virol.
68:7628-7633[Abstract/Free Full Text].
|
| 13.
|
Dardari, R.,
M. Khyatti,
A. Benider,
H. Jouhadi,
A. Kahlain,
C. Cochet,
A. Mansouri,
B. El Gueddari,
A. Benslimane, and I. Joab.
2000.
Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
Int. J. Cancer
86:71-75[CrossRef][Medline].
|
| 14.
|
Drysdale, C. M.,
B. M. Jackson,
R. McVeigh,
E. R. Klebanow,
Y. Bai,
T. Kokubo,
M. Swanson,
Y. Nakatani,
P. A. Weil, and A. G. Hinnebusch.
1998.
The Gcn4p activation domain interacts specifically in vitro with RNA polymerase II holoenzyme, TFIID, and the Ada-Gcn5p coactivator complex.
Mol. Cell. Biol.
18:1711-1724[Abstract/Free Full Text].
|
| 15.
|
Farrell, P. J.,
D. T. Rowe,
C. M. Rooney, and T. Kouzarides.
1989.
Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos.
EMBO J.
8:127-132[Medline].
|
| 16.
|
Feederle, R.,
M. Kost,
M. Baumann,
A. Janz,
E. Drouet,
W. Hammerschmidt, and H. J. Delecluse.
2000.
The Epstein-Barr virus lytic program is controlled by the cooperative functions of two transactivators.
EMBO J.
19:3080-3089[CrossRef][Medline].
|
| 17.
|
Flemington, E. K.,
A. M. Borras,
J. P. Lytle, and S. H. Speck.
1992.
Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain.
J. Virol.
66:922-929[Abstract/Free Full Text].
|
| 18.
|
Gao, Z.,
A. Krithivas,
J. E. Finan,
O. J. Semmes,
S. Zhou,
Y. Wang, and S. D. Hayward.
1998.
The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins.
J. Virol.
72:8559-8567[Abstract/Free Full Text].
|
| 19.
|
Goldman, P. S.,
V. K. Tran, and R. H. Goodman.
1997.
The multifunctional role of the coactivator CBP in transcriptional regulation.
Recent Prog. Horm. Res.
52:103-119.
|
| 20.
|
Greenspan, J. S.,
D. Greenspan,
E. T. Lennette,
D. I. Abrams,
M. A. Conant,
V. Petersen, and U. K. Freese.
1985.
Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.
N. Engl. J. Med.
313:1564-1571[Abstract].
|
| 21.
|
Grossman, S. R.,
M. Perez,
A. L. Kung,
M. Joseph,
C. Mansur,
Z. X. Xiao,
S. Kumar,
P. M. Howley, and D. M. Livingston.
1998.
p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
Mol. Cell
2:405-415[CrossRef][Medline].
|
| 22.
|
Gutsch, D. E.,
E. A. Holley-Guthrie,
Q. Zhang,
B. Stein,
M. A. Blanar,
A. S. Baldwin, and S. C. Kenney.
1994.
The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF- B.
Mol. Cell. Biol.
14:1939-1948[Abstract/Free Full Text].
|
| 23.
|
Ikuta, K.,
Y. Satoh,
Y. Hoshikawa, and T. Sairenji.
2000.
Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children.
Microbes Infect.
2:115-120[CrossRef][Medline].
|
| 24.
|
Jackson, B. M.,
C. M. Drysdale,
K. Nataran, and A. G. Hinnebusch.
1996.
Identification of seven hydrophobic clusters in GCN4 making redundant contributions to transcriptional activation.
Mol. Cell. Biol.
16:5557-5571[Abstract].
|
| 25.
|
Kenney, S. C.,
E. Holley-Guthrie,
E. B. Quinlivan,
D. Gutsch,
Q. Zhang,
T. Bender,
J. F. Giot, and A. Sergeant.
1992.
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.
Mol. Cell. Biol.
12:136-146[Abstract/Free Full Text].
|
| 26.
|
Kieff, E.
1996.
Epstein-Barr virus and its replication, p. 2343-2396.
In
D. Knipe, and P. M. Howley (ed.), Field's virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 27.
|
Kouzarides, T.,
G. Packham,
A. Cook, and P. J. Farrell.
1991.
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper.
Oncogene
6:195-204[Medline].
|
| 28.
|
Kussie, P. H.,
S. Gorina,
V. Marechal,
B. Elenbaas,
J. Moreau,
A. J. Levine, and N. P. Pavletich.
1996.
Structure of the MDMs oncoprotein bound to the p53 tumor suppressor transactivation domain.
Science
274:948-953[Abstract/Free Full Text].
|
| 29.
|
Lieberman, P.
1994.
Identification of functional targets of the Zta transcriptional activator by formation of stable preinitiation complex intermediates.
Mol. Cell. Biol.
14:8365-8375[Abstract/Free Full Text].
|
| 30.
|
Lieberman, P. M., and A. J. Berk.
1990.
In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein.
J. Virol.
64:2560-2568[Abstract/Free Full Text].
|
| 31.
|
Lieberman, P. M., and A. J. Berk.
1994.
A mechanism for TAFs in transcriptional activation: activation domain enhancement of TFIID-TFIIA-promoter DNA complex formation.
Genes Dev.
8:995-1006[Abstract/Free Full Text].
|
| 32.
|
Lieberman, P. M., and A. J. Berk.
1991.
The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction.
Genes Dev.
5:2441-2454[Abstract/Free Full Text].
|
| 33.
|
Lieberman, P. M.,
J. M. Hardwick,
J. Sample,
G. S. Hayward, and S. D. Hayward.
1990.
The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions.
J. Virol.
64:1143-1155[Abstract/Free Full Text].
|
| 34.
|
Lieberman, P. M.,
J. Ozer, and D. B. Gursel.
1997.
Requirement for TFIIA-TFIID recruitment by an activator depends on promoter structure and template competition.
Mol. Cell. Biol.
17:6624-6632[Abstract].
|
| 35.
|
Maul, G. G.
1998.
Nuclear domain 10: the site of DNA virus transcription and replication.
Bioessays
20:660-667[CrossRef][Medline].
|
| 36.
|
Miller, G.
1990.
The switch between latency and replication of Epstein-Barr virus.
J. Infect. Dis.
161:833-844[Medline].
|
| 37.
|
Moriuchi, H.,
M. Moriuchi,
R. Pichyangkura,
S. J. Triezenberg,
S. F. Straus, and J. I. Cohen.
1995.
Hydrophobic cluster analysis predicts an amino-terminal domain of varicella-zoster virus open reading frame 10 required for transcription activation.
Proc. Natl. Acad. Sci. USA
92:9333-9337[Abstract/Free Full Text].
|
| 38.
|
Ozer, J.,
A. H. Bolden, and P. M. Lieberman.
1996.
Transcription factor IIA mutations show activator-specific defects and reveal a IIA function distinct from stimulation of TBP-DNA binding.
J. Biol. Chem.
271:11182-11190[Abstract/Free Full Text].
|
| 39.
|
Ozer, J.,
P. A. Moore,
A. H. Bolden,
A. Lee,
C. A. Rosen, and P. M. Lieberman.
1994.
Molecular cloning of the small ( ) subunit of human TFIIA reveals functions critical for activated transcription.
Genes Dev.
8:2324-2335[Abstract/Free Full Text].
|
| 40.
|
Ptashne, M., and A. Gann.
1997.
Transcriptional activation by recruitment.
Nature
386:569-577[CrossRef][Medline].
|
| 41.
|
Ptashne, M., and A. A. Gann.
1990.
Activators and targets.
Nature
46:329-331.
|
| 42.
|
Regier, J. L.,
F. Shen, and S. J. Triezenberg.
1993.
Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator.
Proc. Natl. Acad. Sci. USA
90:883-887[Abstract/Free Full Text].
|
| 43.
|
Rickinson, A. B., and E. Kieff.
1996.
Epstein-Barr Virus, p. 2397-2446.
In
D. Knipe, and P. M. Howley (ed.), Field's virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Phildelphia, Pa.
|
| 44.
|
Sarisky, R. T.,
Z. Gao,
P. M. Lieberman,
E. D. Fixman,
G. S. Hayward, and S. D. Hayward.
1996.
A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator.
J. Virol.
70:8340-8347[Abstract].
|
| 45.
|
Schepers, A.,
D. Pich, and W. Hammerschmidt.
1993.
A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus.
EMBO J.
12:3921-3929[Medline].
|
| 46.
|
Shang, Y.,
X. Hu,
J. DiRenzo,
M. A. Lazar, and M. Brown.
2000.
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.
Cell
103:843-852[CrossRef][Medline].
|
| 47.
|
Speck, S. H.,
T. Chatila, and E. Flemington.
1997.
Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene.
Trends Microbiol.
5:399-405[CrossRef][Medline].
|
| 48.
|
Takebe, Y.,
M. Seiki,
J.-I. Fujisasa,
P. Hoy,
K. Yokota,
K.-I. Arai,
M. Yoshida, and N. Arai.
1988.
SR promoter: an efficient and versatile mammalian cDNA promoter and R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
Mol. Cell. Biol.
8:466-472[Abstract/Free Full Text].
|
| 49.
|
Tansey, W. P.
2001.
Transcriptional activation: risky business.
Genes Dev.
15:1045-1050[Abstract/Free Full Text].
|
| 50.
|
Uesugi, M.,
O. Nyanguile,
H. Lu,
A. J. Levine, and G. L. Verdine.
1997.
Induced alpha helix in the VP16 activation domain upon binding to a human TAF.
Science
277:1310-1313[Abstract/Free Full Text].
|
| 51.
|
Zerby, D.,
C.-J. Chen,
E. Poon,
D. Lee,
R. Shiekhattar, and P. M. Lieberman.
1999.
The amino-terminal C/H1 domain of CREB binding protein mediates Zta transcription activation of latent Epstein-Barr virus.
Mol. Cell. Biol.
19:1617-1626[Abstract/Free Full Text].
|
| 52.
|
Zhang, Q.,
D. Gutsch, and S. Kenney.
1994.
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.
Mol. Cell. Biol.
14:1929-1938[Abstract/Free Full Text].
|
Journal of Virology, November 2001, p. 10334-10347, Vol. 75, No. 21
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.21.10334-10347.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Countryman, J. K., Gradoville, L., Miller, G.
(2008). Histone Hyperacetylation Occurs on Promoters of Lytic Cycle Regulatory Genes in Epstein-Barr Virus-Infected Cell Lines Which Are Refractory to Disruption of Latency by Histone Deacetylase Inhibitors. J. Virol.
82: 4706-4719
[Abstract]
[Full Text]
-
Wiedmer, A., Wang, P., Zhou, J., Rennekamp, A. J., Tiranti, V., Zeviani, M., Lieberman, P. M.
(2008). Epstein-Barr Virus Immediate-Early Protein Zta Co-Opts Mitochondrial Single-Stranded DNA Binding Protein To Promote Viral and Inhibit Mitochondrial DNA Replication. J. Virol.
82: 4647-4655
[Abstract]
[Full Text]
-
Wang, P., Day, L., Lieberman, P. M.
(2006). Multivalent Sequence Recognition by Epstein-Barr Virus Zta Requires Cysteine 171 and an Extension of the Canonical B-ZIP Domain. J. Virol.
80: 10942-10949
[Abstract]
[Full Text]
-
Kraemer, S. M., Goldstrohm, D. A., Berger, A., Hankey, S., Rovinsky, S. A., Scott Moye-Rowley, W., Stargell, L. A.
(2006). TFIIA Plays a Role in the Response to Oxidative Stress.. Eukaryot Cell
5: 1081-1090
[Abstract]
[Full Text]
-
Wang, P., Day, L., Dheekollu, J., Lieberman, P. M.
(2005). A Redox-Sensitive Cysteine in Zta Is Required for Epstein-Barr Virus Lytic Cycle DNA Replication. J. Virol.
79: 13298-13309
[Abstract]
[Full Text]
-
Liao, G., Huang, J., Fixman, E. D., Hayward, S. D.
(2005). The Epstein-Barr Virus Replication Protein BBLF2/3 Provides an Origin-Tethering Function through Interaction with the Zinc Finger DNA Binding Protein ZBRK1 and the KAP-1 Corepressor. J. Virol.
79: 245-256
[Abstract]
[Full Text]
-
Sinclair, A. J.
(2003). bZIP proteins of human gammaherpesviruses. J. Gen. Virol.
84: 1941-1949
[Abstract]
[Full Text]
-
Deng, Z., Chen, C.-J., Chamberlin, M., Lu, F., Blobel, G. A., Speicher, D., Cirillo, L. A., Zaret, K. S., Lieberman, P. M.
(2003). The CBP Bromodomain and Nucleosome Targeting Are Required for Zta-Directed Nucleosome Acetylation and Transcription Activation. Mol. Cell. Biol.
23: 2633-2644
[Abstract]
[Full Text]
-
Mauser, A., Saito, S.'i., Appella, E., Anderson, C. W., Seaman, W. T., Kenney, S.
(2002). The Epstein-Barr Virus Immediate-Early Protein BZLF1 Regulates p53 Function through Multiple Mechanisms. J. Virol.
76: 12503-12512
[Abstract]
[Full Text]